Inicio › Mieloma múltiple › Wisconsin › Milwaukee
Ensayos clínicos de Mieloma múltiple en Milwaukee, WI
23 estudios para Mieloma múltiple buscan participantes en centros de Milwaukee y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
ReclutandoFase 3
- Medical College of Wisconsin, Milwaukee
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
ReclutandoFase 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
ReclutandoFase 2
- Froedtert & the Medical College of Wisconsin, Milwaukee
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
ReclutandoFase 4
- Froedtert Memorial, Milwaukee
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 3
- Medical College Of Wisconsin, Milwaukee
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 2
- MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ReclutandoFase 3
- Medical College of Wisconsin, Milwaukee
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
ReclutandoFase 1/2
- Medical College of Wisconsin, Milwaukee
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
ReclutandoFase 3
- Research Site, Milwaukee
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutandoFase 3
- Medical College of Wisconsin, Milwaukee
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutandoFase 1/2
- Research Site, Milwaukee
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
Reclutando
- Medical College of Wisconsin, Milwaukee
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ReclutandoFase 3
- Research Site, Milwaukee
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 1/2
- The Medical College of Wisconsin, Milwaukee
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutandoFase 2
- Aurora Cancer Care Milwaukee, Milwaukee
- Aurora St. Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- y 4 más
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ReclutandoFase 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
- y 13 más
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
ReclutandoFase 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
ReclutandoFase 2
- Medical College of Wisconsin, Milwaukee
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
ReclutandoFase 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
ReclutandoFase 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
ReclutandoEstudio observacional
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ReclutandoFase 1
- Froedtert and the Medical College of Wisconsin, Milwaukee
Más información sobre Mieloma múltiple en MedlinePlus
Ensayos de Mieloma múltiple en otras ciudades
- New York City, NY59 estudios
- Boston, MA45 estudios
- Atlanta, GA42 estudios
- Houston, TX39 estudios
- Durham, NC36 estudios
- Nashville, TN31 estudios
- Denver, CO26 estudios
- St. Louis, MO26 estudios
- Rochester, MN25 estudios
- Columbus, OH25 estudios
- Chicago, IL24 estudios
- Baldwin Park, CA23 estudios
Otros estudios en Milwaukee
- Cáncer (todos los tipos)24 estudios
- Cáncer de seno22 estudios
- Cáncer de pulmón de células no pequeñas21 estudios
- Cáncer de pulmón21 estudios
- Linfoma no Hodgkin19 estudios
- Linfoma folicular19 estudios
- Cáncer de próstata19 estudios
- Leucemia mielógena aguda18 estudios
- Cáncer de páncreas18 estudios
- Cáncer de ovario17 estudios
- Linfoma difuso de células B grandes17 estudios
- Linfoma de Burkitt16 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.